# Update on left atrial appendage closure for neurologists

**Authors:** Karl Georg Haeusler, Luciano A Sposato, Marek Grygier, Tatjana Potpara, Jens Erik Nielsen-Kudsk, Lucas V A Boersma, Gregory Y H Lip, Renate B Schnabel, Pavel Osmancik, Boris Schmidt, Wolfram Döhner, Jan Kovac, A John Camm

PMC · DOI: 10.1093/esj/aakaf018 · European Stroke Journal · 2026-01-01

## TL;DR

This paper updates neurologists on using left atrial appendage closure as an alternative to anticoagulation for stroke prevention in atrial fibrillation patients.

## Contribution

The paper provides a focused summary and update of practical guidance on left atrial appendage closure for neurologists.

## Key findings

- Many AF patients are undertreated for stroke prevention despite available anticoagulants.
- Percutaneous left atrial appendage closure is increasingly favored for high-risk patients.
- The procedure has improved safety and is considered when anticoagulation is ineffective or risky.

## Abstract

A significant proportion of patients with atrial fibrillation (AF) who need thromboembolic protection are not treated with or discontinue oral anticoagulation after its initiation. Undertreatment in clinical practice has not improved sufficiently despite the availability of direct oral anticoagulants, which are associated with less intracranial bleeding than vitamin K antagonists. Multiple reasons account for this phenomenon, including bleeding events or ischemic strokes while on anticoagulation, poor treatment adherence despite best educational attempts, or aversion to drug therapy. Percutaneous left atrial appendage (LAA) closure was introduced as an alternative to pharmacological therapy in AF patients in the early 2000s. Due to significant improvements in procedural safety over the years, left atrial appendage closure (LAAC), predominantly achieved through a percutaneous catheter-based device implantation approach, is increasingly favoured for preventing thromboembolic events in patients who cannot achieve effective anticoagulation or have a high hemorrhagic risk. This focused summary and update of a recently published practical guide, developed within guideline/guidance boundaries, provides a perspective of current evidence of potential indications, benefits, complications and limitations of LAAC for neurologists and stroke physicians who may consider this increasingly utilised therapy.

Graphical abstract

## Linked entities

- **Diseases:** atrial fibrillation (MONDO:0004981), stroke (MONDO:0005098)

## Full-text entities

- **Diseases:** AF (MESH:D001281), bleeding (MESH:D006470), intracranial bleeding (MESH:D013345), stroke (MESH:D020521), thromboembolic (MESH:D013923), ischemic strokes (MESH:D002544)
- **Chemicals:** oral anticoagulants (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12866672/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12866672/full.md

## References

130 references — full list in the complete paper: https://tomesphere.com/paper/PMC12866672/full.md

---
Source: https://tomesphere.com/paper/PMC12866672